Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption

被引:55
|
作者
Tam, D [1 ]
Tirona, RG [1 ]
Pang, KS [1 ]
机构
[1] Univ Toronto, Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 2S2, Canada
关键词
D O I
10.1124/dmd.31.4.373
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recently, a physiologically-based, segregated flow model that incorporates separate intestinal tissue and flow to both a nonabsorptive and an absorptive outermost layer (enterocytes) was shown to better describe the observations on route-dependent morphine glucuronidation in the rat small intestine than a traditional physiologically-based model. These theoretical models were expanded, as the segmental segregated flow model and the segmental traditional model, to view the intestine as three segments of equal lengths receiving equal flows to accommodate heterogeneities in segmental transporter and metabolic functions. The influence of heterogeneity in absorptive, exsorptive, and metabolic functions on drug clearance, bioavailability (F), and metabolite formation after intravenous and oral dosing was examined for the intestine when the tissue was the only organ of removal. Simulations were performed for first-order conditions, when drug partitioned readily (flow-limited distribution) or less readily (membrane-limited distribution) into intestinal tissue, and for different gastrointestinal transit times. The intestinal clearance was found to be inversely related to the rate constant for absorption of a drug that was subjected to secretion and was positively correlated with the metabolic and secretory intrinsic clearances. F was positively correlated with the absorption rate constant but was inversely related to the metabolic and secretory intrinsic clearances. The gastrointestinal transit time decreased metabolite formation, increased clearance, and decreased F. The simulations further showed that a descending metabolic intrinsic clearance yielded a lower F and an ascending segmental distribution of metabolic intrinsic clearance yielded a higher F.
引用
收藏
页码:373 / 383
页数:11
相关论文
共 50 条
  • [21] EFFECTS OF ANTIOXIDANTS IN DRUG PRODUCTS ON INTESTINAL DRUG TRANSPORTERS
    Koleske, M.
    Kulkarni, C.
    Alam, K.
    Raw, A.
    Rege, B.
    Zhao, L.
    Lu, D.
    Zhang, L.
    Giacomini, K.
    Kroetz, D.
    Yee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S85 - S85
  • [22] Flavonoids as modulators of metabolic enzymes and drug transporters
    Miron, Anca
    Aprotosoaie, Ana Clara
    Trifan, Adriana
    Xiao, Jianbo
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2017, 1398 (01) : 152 - 167
  • [23] METHYLXANTHINES AND INTESTINAL DRUG ABSORPTION
    BEUBLER, E
    LEMBECK, F
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1976, 292 (01) : 73 - 77
  • [24] Intestinal drug transporters in pathological states: an overview
    Marek Drozdzik
    Izabela Czekawy
    Stefan Oswald
    Agnieszka Drozdzik
    Pharmacological Reports, 2020, 72 : 1173 - 1194
  • [25] Intestinal drug transporters in pathological states: an overview
    Drozdzik, Marek
    Czekawy, Izabela
    Oswald, Stefan
    Drozdzik, Agnieszka
    PHARMACOLOGICAL REPORTS, 2020, 72 (05) : 1173 - 1194
  • [26] Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions
    Zakeri-Milani, Parvin
    Valizadeh, Hadi
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (06) : 859 - 871
  • [27] Development and physiological regulation of intestinal lipid absorption.: III.: Intestinal transporters and cholesterol absorption
    Hui, David Y.
    Labonte, Eric D.
    Howles, Philip N.
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2008, 294 (04): : G839 - G843
  • [28] Expression of intestinal drug transporter proteins and metabolic enzymes in neonatal and pediatric patients
    de Waal, Tom
    Handin, Niklas
    Brouwers, Joachim
    Miserez, Marc
    Hoffman, Ilse
    Rayyan, Maissa
    Artursson, Per
    Augustijns, Patrick
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 654
  • [29] ONTOGENY OF SMALL INTESTINAL DRUG TRANSPORTERS AND METABOLIZING ENZYMES BASED ON TARGETED PROTEIN QUANTIFICATION.
    Kiss, M.
    Mbasu, R.
    Nicolai, J.
    Barnouin, K.
    Kotian, A.
    Mooij, M.
    Wijnen, R.
    Ungell, A.
    Cutler, P.
    Russel, F.
    de Wildt, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S22 - S23
  • [30] ONTOGENY OF SMALL INTESTINAL DRUG TRANSPORTERS AND METABOLIZING ENZYMES BASED ON TARGETED PROTEIN QUANTIFICATION.
    Kiss, M.
    Mbasu, R.
    Nicolai, J.
    Barnouin, K.
    Kotian, A.
    Mooij, M.
    Wijnen, R.
    Ungell, A.
    Cutler, P.
    Russel, F.
    de Wildt, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S85 - S86